Logo image of MCRB

SERES THERAPEUTICS INC (MCRB) Stock Fundamental Analysis

NASDAQ:MCRB - Nasdaq - US81750R1023 - Common Stock - Currency: USD

0.8056  -0.03 (-3.02%)

After market: 0.8284 +0.02 (+2.83%)

Fundamental Rating

2

Taking everything into account, MCRB scores 2 out of 10 in our fundamental rating. MCRB was compared to 572 industry peers in the Biotechnology industry. MCRB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MCRB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MCRB had negative earnings in the past year.
In the past year MCRB has reported a negative cash flow from operations.
MCRB had negative earnings in each of the past 5 years.
MCRB had negative operating cash flow in 4 of the past 5 years.
MCRB Yearly Net Income VS EBIT VS OCF VS FCFMCRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M -200M -250M

1.2 Ratios

Looking at the Return On Assets, with a value of -14.25%, MCRB belongs to the top of the industry, outperforming 83.89% of the companies in the same industry.
With a Return On Equity value of -106.51%, MCRB perfoms like the industry average, outperforming 44.25% of the companies in the same industry.
Industry RankSector Rank
ROA -14.25%
ROE -106.51%
ROIC N/A
ROA(3y)-40.64%
ROA(5y)-40.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MCRB Yearly ROA, ROE, ROICMCRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MCRB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MCRB Yearly Profit, Operating, Gross MarginsMCRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K

More info and screens

4

2. Health

2.1 Basic Checks

MCRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MCRB has more shares outstanding
MCRB has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, MCRB has a worse debt to assets ratio.
MCRB Yearly Shares OutstandingMCRB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
MCRB Yearly Total Debt VS Total AssetsMCRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -9.47, we must say that MCRB is in the distress zone and has some risk of bankruptcy.
MCRB has a worse Altman-Z score (-9.47) than 73.10% of its industry peers.
There is no outstanding debt for MCRB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.47
ROIC/WACCN/A
WACC13.27%
MCRB Yearly LT Debt VS Equity VS FCFMCRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M -200M

2.3 Liquidity

MCRB has a Current Ratio of 1.12. This is a normal value and indicates that MCRB is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.12, MCRB is doing worse than 86.37% of the companies in the same industry.
MCRB has a Quick Ratio of 1.12. This is a normal value and indicates that MCRB is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of MCRB (1.12) is worse than 84.60% of its industry peers.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 1.12
MCRB Yearly Current Assets VS Current LiabilitesMCRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for MCRB have decreased by -6.25% in the last year.
MCRB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -99.95%.
The Revenue has been growing by 34.88% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-6.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.7%
Revenue 1Y (TTM)-99.95%
Revenue growth 3Y56.12%
Revenue growth 5Y34.88%
Sales Q2Q%-100%

3.2 Future

MCRB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 43.10% yearly.
MCRB is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y87.91%
EPS Next 2Y19.78%
EPS Next 3Y12.55%
EPS Next 5Y43.1%
Revenue Next Year-100%
Revenue Next 2Y-43.88%
Revenue Next 3Y-46.49%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MCRB Yearly Revenue VS EstimatesMCRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
MCRB Yearly EPS VS EstimatesMCRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MCRB. In the last year negative earnings were reported.
Also next year MCRB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MCRB Price Earnings VS Forward Price EarningsMCRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MCRB Per share dataMCRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as MCRB's earnings are expected to grow with 12.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.78%
EPS Next 3Y12.55%

More info and screens

0

5. Dividend

5.1 Amount

MCRB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SERES THERAPEUTICS INC

NASDAQ:MCRB (2/4/2025, 8:00:00 PM)

After market: 0.8284 +0.02 (+2.83%)

0.8056

-0.03 (-3.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)N/A N/A
Inst Owners45.37%
Inst Owner Change0.74%
Ins Owners0.46%
Ins Owner Change9.31%
Market Cap137.55M
Analysts75.38
Price Target3.95 (390.32%)
Short Float %13.69%
Short Ratio7.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.27%
Min EPS beat(2)-51.81%
Max EPS beat(2)21.28%
EPS beat(4)3
Avg EPS beat(4)7.17%
Min EPS beat(4)-51.81%
Max EPS beat(4)36.89%
EPS beat(8)4
Avg EPS beat(8)0.85%
EPS beat(12)4
Avg EPS beat(12)-3.47%
EPS beat(16)6
Avg EPS beat(16)10.44%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.51%
EPS NQ rev (1m)-1.35%
EPS NQ rev (3m)16.83%
EPS NY rev (1m)0%
EPS NY rev (3m)89.02%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2149.19
P/FCF N/A
P/OCF N/A
P/B 5.75
P/tB 5.75
EV/EBITDA N/A
EPS(TTM)-1.19
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.92
OCFYN/A
SpS0
BVpS0.14
TBVpS0.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.25%
ROE -106.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.64%
ROA(5y)-40.2%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.33%
Cap/Sales 1820.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.12
Quick Ratio 1.12
Altman-Z -9.47
F-Score2
WACC13.27%
ROIC/WACCN/A
Cap/Depr(3y)145.57%
Cap/Depr(5y)91.76%
Cap/Sales(3y)50.41%
Cap/Sales(5y)31.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.7%
EPS Next Y87.91%
EPS Next 2Y19.78%
EPS Next 3Y12.55%
EPS Next 5Y43.1%
Revenue 1Y (TTM)-99.95%
Revenue growth 3Y56.12%
Revenue growth 5Y34.88%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-43.88%
Revenue Next 3Y-46.49%
Revenue Next 5Y-14.87%
EBIT growth 1Y0.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.56%
EBIT Next 3Y1.74%
EBIT Next 5YN/A
FCF growth 1Y32.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31%
OCF growth 3YN/A
OCF growth 5YN/A